However, the real-world utilisation of renin-angiotensin inhibitors in CKD patients varies between 58 and 64% [27–29], and hence a longer period of registry follow-up is required to evaluate their impact on the incidence of ESKD in ADPKD. Here, REN is linked to chronic kidney disease.